Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 2
1977 2
1978 1
1980 1
1981 5
1983 1
1984 1
1985 4
1986 3
1988 1
1989 4
1990 3
1991 2
1992 3
1994 4
1995 3
1996 1
1998 2
2000 4
2001 11
2002 9
2003 11
2004 16
2005 13
2006 14
2007 4
2008 8
2009 11
2010 8
2011 13
2012 10
2013 9
2014 11
2015 21
2016 25
2017 13
2018 12
2019 5
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Pardanani A, et al. Among authors: kuliczkowski k. JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590. JAMA Oncol. 2015. PMID: 26181658 Clinical Trial.
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. van Imhoff GW, et al. Among authors: kuliczkowski k. J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029326 Clinical Trial.
The role of hypoxia-inducible factors in leukemias.
Szymczak D, Dybko J, Kuliczkowski K. Szymczak D, et al. Among authors: kuliczkowski k. Adv Clin Exp Med. 2018 Feb;27(2):271-275. doi: 10.17219/acem/69261. Adv Clin Exp Med. 2018. PMID: 29521072 Free article. Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
microRNAs: fine tuning of erythropoiesis.
Listowski MA, Heger E, Bogusławska DM, Machnicka B, Kuliczkowski K, Leluk J, Sikorski AF. Listowski MA, et al. Among authors: kuliczkowski k. Cell Mol Biol Lett. 2013 Mar;18(1):34-46. doi: 10.2478/s11658-012-0038-z. Epub 2012 Nov 3. Cell Mol Biol Lett. 2013. PMID: 23124859 Free PMC article. Review.
[Mastocytosis--diagnostic criteria and treatment].
Dereń-Wagemann I, Kuliszkiewicz-Janus M, Kuliczkowski K. Dereń-Wagemann I, et al. Among authors: kuliczkowski k. Postepy Hig Med Dosw (Online). 2009 Nov 26;63:564-76. Postepy Hig Med Dosw (Online). 2009. PMID: 20009120 Free article. Review. Polish.
COVID-19 therapies: do we see substantial progress?
Matusewicz L, Golec M, Czogalla A, Kuliczkowski K, Konka A, Zembala-John J, Sikorski AF. Matusewicz L, et al. Among authors: kuliczkowski k. Cell Mol Biol Lett. 2022 May 31;27(1):42. doi: 10.1186/s11658-022-00341-9. Cell Mol Biol Lett. 2022. PMID: 35641916 Free PMC article.
Bone marrow adipocytes in haematological malignancies.
Frączak E, Olbromski M, Piotrowska A, Glatzel-Plucińska N, Dzięgiel P, Dybko J, Kuliczkowski K, Wróbel T. Frączak E, et al. Among authors: kuliczkowski k. Acta Histochem. 2018 Jan;120(1):22-27. doi: 10.1016/j.acthis.2017.10.010. Epub 2017 Nov 14. Acta Histochem. 2018. PMID: 29146005
250 results